AbbVie (NYSE: ABBV) is a global, research-driven biopharmaceutical company formed in 2013 following its separation from Abbott Laboratories. AbbVie develops and commercializes therapeutics across immunology (Humira, Skyrizi, Rinvoq), oncology (Imbruvica, Venclexta, Epkinly), neuroscience (Vraylar, Duopa), and aesthetics (Botox, Juvederm), with growing investments in oncology, neuroscience, and eye care.
AbbVie's telisotuzumab adizutecan (Temab-A) received two FDA Breakthrough Therapy Designations, in colorectal cancer and non-small cell lung cancer.
AbbVie and Genmab are touting a much-anticipated first-line win for | Epkinly plus R-CHOP cut the risk of progression or death by 51% compared with R-CHOP alone in newly diagnosed DLBCL, setting up a potential first-line challenge to Roche’s Polivy.
AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse large B cell lymphoma—potentially setting up a battle with Roche's Polivy.
The first drug from AbbVie's $8.7 billion takeover of Cerevel two years ago, Parkinson's disease therapy Juvmo, has won FDA approval.
Apogee buy delivers eczema trial win for AbbVie
AbbVie wins FDA approval for Parkinson's drug from $8.7B Cerevel takeover
AbbVie's JUVMO (tavapadon) is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease. The once-daily tablet works with or without levodopa, and the approval is supported by the Phase 3 TEMPO programme.
AbbVie eyes Qulipta expansion after menstrual migraine win — latest pharmaceutical industry news.
AbbVie bispecific shows promise in ph. 3 multiple myeloma trial
Article from BioSpace about AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study.
AbbVie taps '26 cohort of immunology scholarship recipients
AbbVie raised its full-year sales guidance on the strength of Skyrizi, whose momentum is holding up against Johnson & Johnson's rival drug Icotyde.
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
Pfizer plots Litfulo vitiligo filings, pressuring Incyte, AbbVie
Amgen, AbbVie say IRA negotiations impacted Q1 sales — Endpoints News coverage of biopharma industry developments.
AbbVie and Genmab's latest win brings Epkinly closer to label expansion — Endpoints News coverage of biopharma industry developments.
Epkinly (epcoritamab), the AbbVie/Genmab bispecific antibody, showed a significant progression-free survival benefit in combination with rituximab and lenalidomide for relapsed/refractory DLBCL in a Phase 3 trial.
AbbVie scooped up immunology player Apogee Therapeutics for nearly $11 billion in one of the year’s top deals to-date, while Sanofi made a big play to survive its upcoming Dupixent patent cliff; FDA uncertainty continues as the agency changes direction on gene therapies by uniQure and REGENXBIO;…
Fierce Biotech reports AbbVie is acquiring Apogee Therapeutics for $10.9B to gain control of a late-phase eczema drug candidate that could compete with Lilly, Regeneron, and Sanofi.
AbbVie announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion, deepening its immunology pipeline with clinical-stage candidates including APG777 (anti-IL-13) for atopic dermatitis.
AbbVie sharpens immunology focus with $10.9 billion Apogee deal. (Reuters Biopharma.)
Chairman and Chief Executive Officer